Clinical trial
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory…
NCT00183820 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00183820 |
|---|---|
| Title | Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma |
| Official title | A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Testicular Cancer, Germ Cell Neoplasm |
| Intervention type | Drug |
| Interventions | paclitaxel, gemcitabine, and oxaliplatin |
| Enrollment | 30 |
| Start date | Nov 1, 2004 |
| Primary completion | Dec 1, 2015 |
| Completion | Aug 1, 2016 |
| First posted | Sep 16, 2005 |
| Last update posted | Jul 7, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: